Developer docs
API playgroundTry for free, no card

Search company profiles

OptiScan Biomedical

Full company profile

uuid0002tue

Namestring
OptiScan Biomedical
Company typeenum
Private
Founded yearint
1994
Descriptiontext

OptiScan Biomedical is a privately held medical device company headquartered in Hayward, California, founded in 1994. The company develops glucose monitoring systems intended to assist healthcare providers in managing patient glucose levels in clinical settings, positioning it in the inpatient continuous glucose monitoring (CGM) segment — distinct from consumer-focused CGM manufacturers.

The company has raised approximately $165 million across at least seven disclosed funding rounds between 2005 and 2019, drawing a diverse institutional and strategic investor base that includes Johnson & Johnson Development Corporation, MedVenture Associates, Morgenthaler Ventures, Wexford Capital, JPMorgan Partners, NGN Capital, Mitsui Global Investment, Wellcome Trust, Oakwood Medical Investors, EGS Healthcare Capital Partners, and Prism Venture Management. Its long R&D-to-commercialization cycle and sustained capital deployment are consistent with a Class II/III medical device requiring multi-year FDA clinical validation. The company operates with a 51-100 employee headcount.

Peter R. Rule serves as Chief Executive Officer. With no disclosed revenue, customer accounts, or product launch dates in the available data, the company's go-to-market is presumed to follow a capital equipment + recurring consumables model targeting hospital ICUs and surgical settings, though commercial scale remains unverified.

Short descriptiontext

OptiScan Biomedical develops glucose monitoring systems that help healthcare providers manage patient glucose levels in clinical settings, targeting the inpatient continuous glucose monitoring segment.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
continuous glucose monitoring, hospital glucose monitoring, medical device manufacturing, bedside glucose analysis, in-patient glucose monitoring
Industry3 codes
PRIMARYHLAHAOAB
Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Continuous Glucose Monitoring Medical Devices
Social media profiles1 record
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OptiScan Biomedical develops and manufactures glucose monitoring systems intended to assist healthcare providers in measuring and managing patient glucose levels in clinical settings. The company's systems are designed for hospital-based, bedside patient monitoring rather than personal consumer use.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Glucose Monitoring System
CategoryContinuous Glucose Monitoring Medical Devices
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dexcom is the dominant continuous glucose monitor (CGM) manufacturer, primarily consumer-facing but increasingly expanding into inpatient and hospital use cases. It competes with OptiScan for glucose monitoring mindshare and hospital formulary adoption.

TypeEmerging player
Description

Senseonics develops the Eversense implantable CGM, an emerging long-duration CGM technology with potential hospital applications. It overlaps with OptiScan's clinical glucose monitoring focus from a different technological approach.

TypeEmerging player
Description

Nemaura is developing non-invasive and continuous glucose monitoring technologies (sugarBEAT) targeting consumer and clinical applications. It is an emerging competitor whose success would erode OptiScan's positioning in glucose monitoring.

TypeBroad incumbent
Description

Roche is a global leader in hospital blood glucose meters and centralized lab glucose testing through its cobas and Accu-Chek lines. It competes with OptiScan across hospital POC glucose measurement and integrated clinical chemistry workflows.

TypeDirect peer
Description

Nova Biomedical manufactures point-of-care and hospital blood gas, chemistry, and glucose analyzers used in ICUs and clinical labs. It directly overlaps with OptiScan's provider-facing glucose monitoring focus and competes for the same hospital capital equipment budgets.

TypeDirect peer
Description

Ascensia (spun out of Bayer's diabetes care business and now owned by PHC Holdings) markets the CONTOUR line of blood glucose monitoring systems, including healthcare professional versions. It directly competes with OptiScan in glucose monitoring for providers and patients.

TypeBroad incumbent
Description

Abbott's FreeStyle Libre is the leading consumer CGM and is actively expanding into hospital, surgical, and critical care settings. As a broad incumbent with global scale, Abbott represents a primary competitive threat to OptiScan's clinical positioning.

TypeDirect peer
Description

LifeScan (historically part of Johnson & Johnson, which is also an OptiScan investor) markets the OneTouch line of blood glucose monitoring systems, including professional and hospital use cases. It is a directly comparable peer in glucose monitoring devices for providers.

TypeBroad incumbent
Description

Medtronic offers the Guardian CGM and the MiniMed automated insulin delivery system, and has pursued hospital glucose management initiatives. It overlaps with OptiScan in clinical glucose monitoring and integrated insulin delivery.

TypeRegional player
Description

Ypsomed is a Swiss-based diabetes care company that manufactures insulin delivery systems and blood glucose monitoring accessories, primarily serving European markets. It overlaps with OptiScan in diabetes care devices and consumables.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OptiScan Biomedical

Continuous Glucose Monitoring Medical Devicesoptiscancorp.com

OptiScan Biomedical develops glucose monitoring systems that help healthcare providers manage patient glucose levels in clinical settings, targeting the inpatient continuous glucose monitoring segment.

What OptiScan Biomedical does

OptiScan Biomedical is a privately held medical device company headquartered in Hayward, California, founded in 1994. The company develops glucose monitoring systems intended to assist healthcare providers in managing patient glucose levels in clinical settings, positioning it in the inpatient continuous glucose monitoring (CGM) segment — distinct from consumer-focused CGM manufacturers.

The company has raised approximately $165 million across at least seven disclosed funding rounds between 2005 and 2019, drawing a diverse institutional and strategic investor base that includes Johnson & Johnson Development Corporation, MedVenture Associates, Morgenthaler Ventures, Wexford Capital, JPMorgan Partners, NGN Capital, Mitsui Global Investment, Wellcome Trust, Oakwood Medical Investors, EGS Healthcare Capital Partners, and Prism Venture Management. Its long R&D-to-commercialization cycle and sustained capital deployment are consistent with a Class II/III medical device requiring multi-year FDA clinical validation. The company operates with a 51-100 employee headcount.

Peter R. Rule serves as Chief Executive Officer. With no disclosed revenue, customer accounts, or product launch dates in the available data, the company's go-to-market is presumed to follow a capital equipment + recurring consumables model targeting hospital ICUs and surgical settings, though commercial scale remains unverified.

OptiScan Biomedical firmographics

Firmographics
Name
OptiScan Biomedical
Website
https://optiscancorp.com
Company type
Private
Founded year
1994
Headcount range
51–100 employees
Short description
OptiScan Biomedical develops glucose monitoring systems that help healthcare providers manage patient glucose levels in clinical settings, targeting the inpatient continuous glucose monitoring segment.
Ownership category
akta.pro rank

OptiScan Biomedical industry classification

Industry
Product category
Continuous Glucose Monitoring Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAB
Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Continuous glucose monitoring
  • Hospital glucose monitoring
  • Medical device manufacturing
  • Bedside glucose analysis
  • In-patient glucose monitoring

Where OptiScan Biomedical is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Markets served

OptiScan Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

OptiScan Biomedical product offering

Product offering

Core offering

OptiScan Biomedical develops and manufactures glucose monitoring systems intended to assist healthcare providers in measuring and managing patient glucose levels in clinical settings. The company's systems are designed for hospital-based, bedside patient monitoring rather than personal consumer use.

Differentiator

Problem solved

Functional benefit

Products and services

  • Glucose Monitoring System

Companies that use OptiScan Biomedical

Customer profile

Ideal customer profiles1 record

OptiScan Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OptiScan Biomedical partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

OptiScan Biomedical competitors and assessment

Company assessment

Broad incumbents

  • Dexcom: Dexcom is the dominant continuous glucose monitor (CGM) manufacturer, primarily consumer-facing but increasingly expanding into inpatient and hospital use cases. It competes with OptiScan for glucose monitoring mindshare and hospital formulary adoption.
  • Roche Diagnostics: Roche is a global leader in hospital blood glucose meters and centralized lab glucose testing through its cobas and Accu-Chek lines. It competes with OptiScan across hospital POC glucose measurement and integrated clinical chemistry workflows.
  • Abbott Diabetes Care: Abbott's FreeStyle Libre is the leading consumer CGM and is actively expanding into hospital, surgical, and critical care settings. As a broad incumbent with global scale, Abbott represents a primary competitive threat to OptiScan's clinical positioning.
  • Medtronic Diabetes: Medtronic offers the Guardian CGM and the MiniMed automated insulin delivery system, and has pursued hospital glucose management initiatives. It overlaps with OptiScan in clinical glucose monitoring and integrated insulin delivery.

Emerging players

  • Senseonics Holdings: Senseonics develops the Eversense implantable CGM, an emerging long-duration CGM technology with potential hospital applications. It overlaps with OptiScan's clinical glucose monitoring focus from a different technological approach.
  • Nemaura Medical: Nemaura is developing non-invasive and continuous glucose monitoring technologies (sugarBEAT) targeting consumer and clinical applications. It is an emerging competitor whose success would erode OptiScan's positioning in glucose monitoring.

Direct peers

  • Nova Biomedical: Nova Biomedical manufactures point-of-care and hospital blood gas, chemistry, and glucose analyzers used in ICUs and clinical labs. It directly overlaps with OptiScan's provider-facing glucose monitoring focus and competes for the same hospital capital equipment budgets.
  • Ascensia Diabetes Care: Ascensia (spun out of Bayer's diabetes care business and now owned by PHC Holdings) markets the CONTOUR line of blood glucose monitoring systems, including healthcare professional versions. It directly competes with OptiScan in glucose monitoring for providers and patients.
  • LifeScan: LifeScan (historically part of Johnson & Johnson, which is also an OptiScan investor) markets the OneTouch line of blood glucose monitoring systems, including professional and hospital use cases. It is a directly comparable peer in glucose monitoring devices for providers.

Regional players

  • Ypsomed: Ypsomed is a Swiss-based diabetes care company that manufactures insulin delivery systems and blood glucose monitoring accessories, primarily serving European markets. It overlaps with OptiScan in diabetes care devices and consumables.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

OptiScan Biomedical social profiles

Digital presence

OptiScan Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OptiScan Biomedical leadership team

Management profile

Number of profiles

Profiles1 record

OptiScan Biomedical funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OptiScan Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OptiScan Biomedical

What does OptiScan Biomedical do?

OptiScan Biomedical develops and manufactures glucose monitoring systems intended to assist healthcare providers in measuring and managing patient glucose levels in clinical settings. The company's systems are designed for hospital-based, bedside patient monitoring rather than personal consumer use.

When was OptiScan Biomedical founded?

OptiScan Biomedical was founded in 1994. It employs 51 to 100 people.

Where is OptiScan Biomedical based?

OptiScan Biomedical is headquartered in Hayward, United States, in the North America region.

Who are OptiScan Biomedical's main competitors?

Broad incumbents on record are Dexcom, Roche Diagnostics, Abbott Diabetes Care and Medtronic Diabetes. Emerging players are Senseonics Holdings and Nemaura Medical. Direct peers are Nova Biomedical, Ascensia Diabetes Care and LifeScan. Ypsomed is listed as a regional player.

Does OptiScan Biomedical have an API?

No public API is recorded for OptiScan Biomedical.

What industry is OptiScan Biomedical in?

OptiScan Biomedical's product category is Continuous Glucose Monitoring Medical Devices. Its primary akta.pro industry code is HLAHAOAB, Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate), with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOptiScan Biomedical Receives CE Mark for OptiScanner® 7000 for Automated Multivariate Monitoring of Metabolic and Hemodynamic Status of Patients in the Intensive Care UnitOptiScan Biomedical Corporation received CE Mark certification for its OptiScanner 7000 continuous blood monitoring device, enabling the company to market and sell the product across the 30 countries of the European Economic Area. The device represents an advancement over existing intermittent monitoring technologies by automatically measuring and trending glucose, lactate, and central venous oxygen saturation levels from a single micro-sample of blood every 15 minutes. The certification allows the system to address critical care monitoring needs, particularly for ICU patients with sepsis, where early detection of metabolic and hemodynamic changes is crucial for patient outcomes.FierceBiotechOptiScan reels in $20M for broad rollout of automated bedside glucose monitoring systemOptiScan raised $20 million in series E financing to broaden its automated bedside glucose monitoring system and expand into other analytes. The system, FDA-cleared in 2017, provides continuous glucose readings every 15 minutes for ICU patients. The company plans wider commercialization in 2020 and a follow-up device for lactate monitoring.PR NewswireOptiScan Biomedical Completes $20 Million Series E FinancingOptiScan Biomedical Corporation announced the closing of a $20 million Series E financing round to support commercialization of its OptiScanner 5000 continuous glucose monitoring system in the United States and expand its platform to monitor additional analytes for critically ill patients. The company presented clinical data from its 200-patient MANAGE IDE study at the 39th International Symposium on Intensive Care and Emergency Medicine in Brussels, demonstrating the platform's ability to provide trending lactate levels at the bedside every 15 minutes. OptiScan expects post-market studies supporting ICU continuous monitoring to complete in the coming months as part of its U.S. commercial launch preparations.HIT ConsultantOptiScan Biomedical Nabs $20M for FDA-Cleared Continuous Glucose Bedside Monitor for ICUOptiScan Biomedical raised $20 million in Series E funding to commercialize its FDA-cleared OptiScanner 5000 continuous glucose monitor for ICU use. The company will use the funds for U.S. launch and expanding the platform to monitor additional analytes, with post-market studies expected to complete in coming months.PR NewswireOptiScan Biomedical Announces Appointment of Cary G. Vance as President and Chief Executive OfficerOptiScan Biomedical Corporation appointed Cary G. Vance as president and chief executive officer, replacing William Mince who had served as interim CEO since October 2017. Vance brings over 21 years of medical device industry experience, having previously led Myoscience and Hansen Medical, which was acquired by Auris Surgical Robotics in 2016. The company stated that Vance's expertise in commercializing disruptive medical technologies will drive its global hospital market expansion strategy.PR NewswireOptiScan Biomedical's OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICUOptiScan Biomedical received FDA 510(k) clearance for the OptiScanner 5000 Glucose Monitoring System, making it the first inline continuous glucose monitoring device authorized for surgical intensive care unit patients. The clearance was based on a pivotal multi-center clinical trial involving 160 SICU patients that demonstrated the device's safety and accuracy for automated, real-time bedside plasma glucose monitoring with alarms for hyperglycemia and hypoglycemia excursions. The system addresses a significant clinical need, as up to 60 percent of ICU patients experience glucose dysregulation requiring continuous monitoring to maintain glycemic control.PR NewswireOptiScan Biomedical Receives CE Mark for OptiScanner® 6000 Automated Device for Monitoring Multiple Key Analytes in ICU PatientsOptiScan Biomedical Corporation announced that its OptiScanner 6000 automated bedside monitoring device has received CE Mark certification, enabling sale and marketing across the 30 countries of the European Economic Area. The device provides near-continuous tracking of glucose and lactate levels in ICU patients using a single micro-sample of blood, addressing needs for both diabetic and stressed hyperglycemia patients as well as those with critical illnesses such as sepsis. The company plans to initiate marketing in the EU later this year.